Schrodinger (NASDAQ:SDGR) EVP Sells $1,051,200.00 in Stock

Schrodinger, Inc. (NASDAQ:SDGR) EVP Yvonne Tran sold 32,000 shares of the firm’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $32.85, for a total value of $1,051,200.00. Following the transaction, the executive vice president directly owned 52,683 shares in the company, valued at approximately $1,730,636.55. This represents a 37.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Schrodinger Price Performance

NASDAQ:SDGR opened at $30.85 on Friday. The business has a 50 day moving average of $26.74 and a 200 day moving average of $17.39. The company has a market capitalization of $2.28 billion, a price-to-earnings ratio of -39.05 and a beta of 1.69. Schrodinger, Inc. has a 1-year low of $10.94 and a 1-year high of $34.00.

Schrodinger (NASDAQ:SDGR) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.17. The business had revenue of $64.49 million for the quarter, compared to analysts’ expectations of $47.73 million. Schrodinger had a negative net margin of 22.02% and a negative return on equity of 18.12%. The business’s quarterly revenue was up 18.7% on a year-over-year basis. During the same period last year, the business earned ($0.45) earnings per share. As a group, sell-side analysts anticipate that Schrodinger, Inc. will post -1.39 EPS for the current year.

Hedge Funds Weigh In On Schrodinger

Several institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Schrodinger during the second quarter valued at approximately $170,978,000. Rubric Capital Management LP raised its position in shares of Schrodinger by 43.8% during the 1st quarter. Rubric Capital Management LP now owns 6,000,000 shares of the company’s stock valued at $68,160,000 after purchasing an additional 1,828,502 shares during the period. Amova Asset Management Americas Inc. raised its position in shares of Schrodinger by 13.2% during the 1st quarter. Amova Asset Management Americas Inc. now owns 3,190,837 shares of the company’s stock valued at $36,248,000 after purchasing an additional 371,167 shares during the period. Public Sector Pension Investment Board lifted its stake in shares of Schrodinger by 79.0% during the 3rd quarter. Public Sector Pension Investment Board now owns 350,738 shares of the company’s stock valued at $10,890,000 after buying an additional 154,824 shares in the last quarter. Finally, Edgestream Partners L.P. purchased a new position in shares of Schrodinger during the 3rd quarter valued at $5,271,000. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Wall Street Zen raised shares of Schrodinger from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. UBS Group increased their price objective on Schrodinger from $19.00 to $21.00 and gave the stock a “neutral” rating in a report on Tuesday, October 20th. Weiss Ratings raised shares of Schrodinger from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. BMO Capital Markets increased their price target on shares of Schrodinger from $24.00 to $30.00 and gave the stock an “outperform” rating in a research note on Monday, October 12th. Finally, Zacks Research cut Schrodinger from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 3rd. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $26.67.

Schrodinger Company Profile

Schrödinger, Inc. develops computational software used to support drug discovery and materials research. Its platform applies physics-based modeling, computational chemistry and machine learning to help researchers analyze molecular properties and identify promising candidates. The company’s tools are used by pharmaceutical and biotechnology companies, academic institutions and other research organizations. Alongside software sales and subscriptions, Schrödinger works with partners on drug discovery programs and advances a portfolio of its own therapeutic candidates.